Prescription Drug News and Research

RSS

CVS Caremark's integrated businesses help patients achieve better health

CVS Caremark's chief health care strategy officer today outlined how the company's integrated offerings -- retail pharmacy, pharmacy benefit management (PBM) and retail clinics -- are helping patients achieve better health by working to increase medication adherence and targeting behaviors to improve treatment for chronic diseases.

18 Feb 2012

New publication explains role of standards-based interoperable digital identities in healthcare

A new publication explains how standards-based interoperable digital identities are needed to transform healthcare to a paperless and fully electronic business environment. It is being issued in conjunction with the annual meeting of Healthcare Information and Management Systems Society (HIMSS), February 20-24 in Las Vegas.

18 Feb 2012

PCMA launches That's What PBMs Do campaign in Maryland

The Pharmaceutical Care Management Association (PCMA) has launched a new ad campaign in Maryland that highlights the core value proposition of pharmacy benefit managers.

18 Feb 2012

Federal probe of FDA's treatment of whistleblowers widens

Investigators say they are broadening their efforts because of "new and troubling allegations."

18 Feb 2012

Research roundup: Patient satisfaction, community health centers as medical homes, analyzing controversial Medicare coverage

Every week, KHN reporter Shefali S. Kulkarni compiles a selection of recently-released health policy studies and briefs.

18 Feb 2012

FSMB initiatives to raise awareness about opioid prescribing

The Federation of State Medical Boards (FSMB) announced today several initiatives aimed at addressing the rise of opioid abuse and related deaths in the United States, while safeguarding legitimate access to medications for patients with pain.

18 Feb 2012

Alexza prices underwritten public offering of 44,000,000 shares of common stock and warrants

Alexza Pharmaceuticals, Inc., or the Company, today announced that it has priced its previously announced underwritten public offering of 44,000,000 shares of common stock and warrants to purchase 44,000,000 shares of common stock.

17 Feb 2012

Pfizer, Mylan enter settlement agreement to resolve e-cue patent litigation

Mylan Inc. and Pfizer Inc. today announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Intelliject and Sanofi-Aventis that will resolve pending patent litigation related to Intelliject's 505(b)(2) new drug application (NDA) for its epinephrine auto-injector known as e-cue, which will be manufactured and marketed by Sanofi-Aventis.

16 Feb 2012

DEA tries to stem prescription drug abuse by suspending pharmacies

Federal drug agents and one of the nation's biggest drug distributors are heading for a legal showdown that will test the government's strategy of going after larger corporations to fight rampant prescription drug abuse.

16 Feb 2012

State roundup: Legislatures tackling abortion restrictions, Medicaid cuts/revamps, Rx drug abuse

A Republican supermajority has muscled two of the most restrictive anti-abortion bills in years through the Virginia House, including one that would all but outlaw the procedure in the state by declaring that the rights of persons apply from the moment sperm and egg unite. The bills passed over bitter yet futile objections from Democrats. And one GOP delegate caused the House to ripple when he said most abortions come as "matters of lifestyle convenience." ... The bills now go to the Senate

16 Feb 2012

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy.

16 Feb 2012

Dey Pharma to change company name to Mylan Specialty

Mylan Inc. today announced that it plans to change the name of its fully integrated branded specialty pharmaceutical business from Dey Pharma to Mylan Specialty.

16 Feb 2012

FDA accepts Gilead's Truvada sNDA and grants Priority Review

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.

14 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

Research roundup: Predicting the health law's effects on small business, uninsured, disparities

Using a RAND assessment tool, researchers aimed to "predict the effects of self-insurance and grandfathering exemptions on coverage and premiums available" on policies for small businesses sold in the insurance exchanges.

13 Feb 2012

Viewpoints: Contraception as Obama's 'gospel'; The right balance? Freedom at risk?; Examining Medicaid mandate

These guidelines, which increase access to contraceptive services for women while upholding the religious liberty of churches, mosques and synagogues, strike the proper balance between respecting the religious beliefs of all Americans and protecting the health of American women and families. They will reduce health costs, end long-standing gender discrimination in prescription drug coverage and further enable women to lead healthier lives.

13 Feb 2012